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Background: Environmental factors may play a role in colon cancer. In this view, several studies investigated tumor
samples for the presence of various viral DNA with conflicting results.
Findings: We undertook a systematic DNA analysis of 44 consecutive, prospectively collected primary tumor
samples by real time and qualitative PCR for viruses of known or potential oncogenic role in humans, including
polyomavirus (JCV, BKV, Merkel cell polyomavirus), HPV, HTLV, HHV-8 and EBV. Negative controls consisted of surgical
resection margins. No evidence of genomic DNA fragments from tested virus were detected, except for EBV, which
was found in a significant portion of tumors (23/44, 52%). Real-time PCR showed that EBV DNA was present at a highly
variable content (median 258 copies in 105 cells, range 15–4837). Presence of EBV DNA had a trend to be associated
with high lymphocyte infiltration (p = 0.06, χ2 test), and in situ hybridization with EBER1-2 probes revealed latency in a
fraction of these lymphoid cells, with just a few scattered plasma cells positive for BZLF-1, an immediate early protein
expressed during lytic replication. LMP-1 expression was undetectable by immunohistochemistry.
Conclusions: These results argue against a significant involvement of the tested oncogenic viruses in established
colon cancer.
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It is estimated that 16-18% of the global cancer burden
can be associated with oncogenic viruses [1,2]. The
DNA viruses of recognized pathogenic role in humans
include HCV, HBV, HPV, HHV-8, MCPyV and EBV,
while the role of polyomaviruses JCV and BKV is
controversial [1,3]. Colon cancer is a leading cause of
cancer-related death and morbidity in western countries.
The pathogenesis of this cancer is highly complex and it
involves sequential genetic and epigenetic mechanisms
[4,5]. A possible contribution of environmental agents,
including bacteria and viruses, is also considered [6,7].
However, the search for a pathogenic agent generated* Correspondence: v.perfetti@smatteo.pv.it
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unless otherwise stated.conflicting results, possibly related to technical reasons
or other unknown factors [6].
To contribute to this issue, we prospectively collected
a series of consecutive 44 colon cancers to perform
a systematic PCR-analysis for human polyomaviruses
(JCV, BKV, MCPyV), HPV, HTLV, HHV-8 and EBV.
The study was approved by Fondazione IRCCS Policlinico
San Matteo Review Board. Fondazione IRCCS Policlinico
San Matteo Review Board. Clinical and pathology charac-
teristics are reported in Table 1. The population was rep-
resentative of colon cancer cases who underwent primary
tumor resection (low numbers of metastatic cases, Duke’s
stage D). Internal control consisted of surgical resection
margin (at least 5 cm distant from the tumor). Quality of
extracted DNA samples (QIAmp DNA Mini Kit, Qiagen,
Italy) was verified by means of amplification of the house-
keeping gene beta-2-microglobulin (DNA amplicons >105
copies). Positive controls included virus infected humanLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Table 1 Clinical and pathological features of the colon
cancer cases analysed for potential oncogenic viruses





Median of age = 75 years (range 46–84)
≤ 65 years 9 20







Sigmoid - Rectal 10 23
Colon dx 18 41





















Figure 2 EBV lytic phase was limited to a few scatter plasma
cells in the lymphoid infiltrate. Immunohistochemistry with a
monoclonal antibody specific for the early immediate protein
BZLF-1. These findings confirmed that EBV is essentially in latency
phase in the lymphoid infiltrates of colorectal cancers.
Figure 1 EBV latency is restricted to the inflammatory infiltrate
in colon cancer. Tissue RNA in situ hybridization using EBER 1–2
PNA probes to detect EBV latency (Dako, Denmark). A blue nuclear
staining indicates a positive reaction. Epithelial and cancer cells are
negative, whereas occasionally positivity of non-neoplastic lymphoid
cells may be extensive (reaching 20%).
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ples, and plasmid DNA. Amplification methods consisted
of real time (EBV, JCV, BKV, HTLV and HHV-8) [8-11] and
qualitative PCR (MCPyV, HPV) [12,13]. Given the very
controversial evidence concerning JCV, which was found
from 0% to nearly 80% of the tumor samples tested in the
literature [6,14-18], JCV was additionally investigated bythe specific qualitative PCR described in positive reports
[18] and that employed primers spanning a different
portion of the large T antigen. Sensitivity for JCV real-time
PCR assay was 1 viral copy in 105 cells. Experiments
showed that no genomic DNA fragments from the tested
viruses were detectable, with the notable exception of EBV
that was positive in a consistent portion of cases (23/44
samples, 52%). Tumors associated with EBV positivity had
EBV negative surgical resection margins. EBV DNA con-
tent was highly variable in tumors (median 258 viral copies
in 105 cells, range 15–4837), and EBV had a trend to be
observed in tumors displaying high lymphoid infiltration
(p = 0.06, χ2 test). In situ hybridization analyses for the
detection of EBER1-2 RNAs (PNA Probe/FITC and ISH
detection kit, Dako, Denmark) demonstrated virus latency
in a variable fraction of infiltrating non-neoplastic lymphoid
cells, which could reach 20% in a few cases (Figure 1), but
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chemistry to EBNA-1 nuclear protein (Fitzgerald
Industries International – USA, clone M5042521), an
antigen that is expressed during both latent and lytic
phases, failed to show positive nuclei in neoplastic
cells. Immunohistochemistry for LMP-1, a membrane
associated protein involved in activation, was also
negative, while lytic cycle was detected via expression
of the immediate early protein BZLF1 (ZEBRA antigen,
LSBio, clone LS-C102904) in a few scattered plasma
cells (Figure 2). These findings essentially confirm la-
tency of EBV in lymphoid infiltrates. The presence of
EBV was not associated with the other tumor or clin-
ical parameters studied including age, stage, tumor
localization, or the presence of necrosis.
In conclusion, we performed a PCR-based systematic
analysis for potential oncogenic viruses in clinically
established colon cancer and EBV was the only one de-
tected. The viral infection was restricted to latency in
the lymphoid infiltrate, in line with the few reports that
used in situ hybridization with EBER probes [19,20],
while we noted an association with high lymphocyte
infiltration, a well-recognized favorable prognostic par-
ameter. EBV positivity in lymphoid infiltrates may oc-
casionally be extensive (Figure 1), much higher than
expected on the numbers of circulating EBV positive
memory B-lymphocytes in normal individuals, and it
might be of interest to studying this phenomenon in
specifically designed studies. In summary, the present
analysis does not support a significant involvement of
the tested viruses in manifest colon cancer, and sug-
gests that new approaches [21] capable of detecting
known and unknown non-human sequences should be
investigated to study the role of infectious agents in
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